Anthony S. Chilton
Keine laufenden Positionen mehr
Profil
Anthony S.
Chilton served as President, Chief Executive Officer & Director at Inotiv, Inc. from 2011 to 2012.
Prior to that, he was VP-Biopharmaceutical Development Division at Cardinal Health, Inc. and Vice President-PreClinical Development at Genmedica Therapeutics SL.
Chilton received his undergraduate degree from the University of East Anglia in 1981 and his doctorate from the University of Hertfordshire in 1993.
Ehemalige bekannte Positionen von Anthony S. Chilton
| Unternehmen | Position | Ende |
|---|---|---|
| INOTIV, INC. | Präsident | 05.07.2012 |
| CARDINAL HEALTH, INC. | Corporate Officer/Principal | - |
Genmedica Therapeutics SL
 Genmedica Therapeutics SL BiotechnologyHealth Technology Genmedica Therapeutics SL engages in the research and development of new treatments for diabetes. Its has developed novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease. The company was founded by Alec Humayun Mian and Luc Marti Clauzel on June 21, 2004 and is headquartered in Barcelona, Spain. | Corporate Officer/Principal | - |
Ausbildung von Anthony S. Chilton
| University of East Anglia | Undergraduate Degree |
| University of Hertfordshire | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| INOTIV, INC. | Commercial Services |
| CARDINAL HEALTH, INC. | Distribution Services |
| Private Unternehmen | 1 |
|---|---|
Genmedica Therapeutics SL
Genmedica Therapeutics SL BiotechnologyHealth Technology Genmedica Therapeutics SL engages in the research and development of new treatments for diabetes. Its has developed novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease. The company was founded by Alec Humayun Mian and Luc Marti Clauzel on June 21, 2004 and is headquartered in Barcelona, Spain. | Health Technology |
